All In Biotech

Drug Trial Radar · NCT06672536

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Nov 26, 2024

Primary completion

Sep 23, 2026

Study completion Jan 11, 2027

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
Collaborators
Tianjin Medical University Eye Hospital
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.

Conditions

  • nAMD

Interventions

  • SCT520FFDrug

    SCT520FF dose level 1,IVI

  • SCT520FFDrug

    SCT520FF dose level 2,IVI

  • SCT520FFDrug

    SCT520FF dose level 3,IVI

  • EYLEA 2 MGDrug

    EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse events(TEAE)Time frame: From Day 0 up to 196days
  2. Treatment-related treatment emergent adverse events(TRAE)Time frame: From Day 0 up to 196days
  3. Serious adverse event(SAE)Time frame: From Day 0 up to 196days
  4. Adverse event of special interest(AESI)Time frame: From Day 0 up to 196days
  5. Dose limited toxicity(DLT)Time frame: From Day 0 up to 196days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Eye Hospital

    Tianjing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.